Premium

Top 20 therapeutic classes by global pharmaceutical sales in 2015 (in billion U.S. dollars)

Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license
Loading statistic...
Sales in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
© Statista 2017

Show further information

Show sources information

AdvertisementTableau Software
 
About This Statistic

This statistic depicts the top 10 therapeutic classes by global pharmaceutical sales in 2015. In that year, the global pharmaceutical industry generated a total revenue of some 29.5 billion U.S. dollars through dermatologics.


Top therapeutic classes and drugs

Oncologics, pain therapy, and anti-diabetics are among the top global pharmaceuticals based on revenues, generating 79 billion U.S. dollars, 56 billion U.S. dollars, and 71 billion U.S. dollars, respectively, in 2015. In oncologic developments, drugs for non-small cell lung cancer and breast cancer were among the leading diseases in therapeutic drug development. On the other hand, Cymbalta was one of the top serotonin-norepinephrine reuptake inhibitors (SNRIs) in the United States, accounting over 40 percent of the market share. Cymbalta is manufactured by Eli Lilly and used to treat major depressive disorder and generalized anxiety disorder.

One of Bristol-Myers Squibb’s most profitable medications is Abilify, a neurology product that generated revenue of 5.8 billion U.S. dollars in the United States in 2015. Aripiprazole, marketed as Abilify, is used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, among other disorders. Bristol-Myers Squibb’s neuroscience program focuses on the development of therapeutic regimens for disorders that impact the brain and nervous systems. Some of the company’s other therapeutic areas of focus include cardiovascular, immunoscience, and virology.

Show more
Special Functions
Download as ...
Graphic (PNG)
Excel (XLS)
PowerPoint (PPT)
PDF
Options
Settings
Print
Research Alerts
Download started
Please be patient - this may take a moment

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Global pharmaceutical industry"

  • Overview
The most important statistics
  • Companies and products
The most important statistics
  • Top companies by revenue
  • R&D, patents, new entities
  • Outlook
The most important statistics

Related Studies: Available to Download in PDF or PPTX Format

Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions